STING1 and systemic lupus erythematosus: Inhibitors of STING signaling are being developed for inflammatory diseases, such as Aicardi–Goutières syndrome, STING-associated vasculopathy with onset in infancy, and systemic lupus erythematosus [30,63], but the research is limited.